Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) stock has a lot of negative sentiment priced into the shares, maybe too much at this point.
Keep Reading →
May 1 - News
Throughout the years, some of the best performing pharmaceutical industry stocks have had long histories of providing healthy dividends to their stockholders. Merck & Co., Inc...
Keep Reading →
April 30 - News
When I was six years old, something happened to me that I have never forgotten and will probably always live with.
Keep Reading →
April 30 - News
In January of 2012, Business Magazine released a list of the most sustainable companies in the world. You might be surprised to see who topped their list.
Keep Reading →
April 25 - News
Eli Lilly & Co. (NYSE:LLY) notched revenue of $5.60 billion. The 12 analysts polled by S&P Capital IQ expected to see a top line of $5.68 billion on the same basis.
Keep Reading →
April 24 - News
If you own Merck & Co., Inc. (NYSE:MRK) stock, you likely enjoyed the past couple of months.
Keep Reading →
April 23 - News
Tomorrow, Eli Lilly & Co. (NYSE:LLY) will release its latest quarterly results.
Keep Reading →
April 23 - News
If you haven't noticed, it's earnings season once again! Believe it or not, there are times when earnings reports slow down in frequency, but this is certainly not one of those...
Keep Reading →
April 21 - News
As I mentioned previously in Part 1, it was an incredibly busy week for the biotech sector.
Keep Reading →
April 20 - News
The drug produced a statistically significant improvement in three different rating scales for depression compared to placebo.
Keep Reading →
April 17 - News
I had recommended staying away from the company for now because it looked too risky with a long wait before the company could complete its second phase 3 trial for pimavanserin...
Keep Reading →
April 11 - News
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown.
Keep Reading →
April 9 - News
Making money in business typically happens in one of two ways. You either sell a relatively low-cost product to a large number of customers.
Keep Reading →
April 4 - News
Recently, with the loss of patents causing generic competition, the main attraction to pharmaceutical companies has been their dividend.
Keep Reading →
March 29 - News
In this series, we'll highlight four companies in an industry, and compare their "cash king margins" over time, trying to determine which has the greatest likelihood of putting...
Keep Reading →
March 27 - News
Big pharma loves Obamacare, right? After all, the main lobbying group for big pharma, the Pharmaceutical Researchers and Manufacturers of America, or PhRMA, spent $150 million...
Keep Reading →
March 23 - News
The EU's decision to seize the bank accounts of ordinary Cypriot depositors was front and center again as concerns that the financial sector could come under tremendous pressure...
Keep Reading →
March 22 - News
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) is bringing its kids home.
Keep Reading →
March 22 - News
ACADIA Pharmaceuticals Inc.
Keep Reading →
March 22 - News
The demand for drugs worldwide is expected to increase due to emerging markets abroad and more specifically, due to an influx of demand from the aging "Baby Boomers" domestically...
Keep Reading →
March 20 - News
It's not uncommon for me to applaud the pharmaceutical industry as a solid long-term investment.
Keep Reading →
March 19 - News
One thing that many investors become fixated on is always wanting the next 'hot tip' or the 'inside word.' Forever seeking an edge on everyone else, investors seek the holy grail...
Keep Reading →
March 18 - News
With interest rates still sitting near record lows, investors looking for current income have been forced to move from fixed-income positions and into stocks to find yield.
Keep Reading →
March 18 - Dividend Stocks
Global pharmaceutical giants AstraZeneca plc (ADR) (NYSE:AZN), Bristol Myers Squibb Co. (NYSE:BMY), and Eli Lilly & Co. (NYSE:LLY) meet most of the growth and profitability...
Keep Reading →
March 17 - Hedge Funds
The company got a mid-day Food and Drug Administration approval for its lymph node diagnostic Lymphoseek.
Keep Reading →
March 14 - News
Boys will be boys. We fight, we apologize, and we enjoy some cold ones the next day like nothing happened.
Keep Reading →
March 14 - News
For years, satirical late-night TV host Stephen Colbert has been running a series on his show called "Better Know a District," which highlights one of the 435 U.S.
Keep Reading →
March 12 - News
One of my favorite Warren Buffett quotes is that it’s far better to buy a wonderful company trading at a fair price than a fair company trading at a wonderful price. While...
Keep Reading →
March 10 - News
Ultimately, that was the loss of those optimists. As value investors, we are not afraid of bad news as long as we get compensated by low valuations.
Keep Reading →
March 7 - News
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Keep Reading →
March 7 - News
Eight months ago, Bayer and Johnson & Johnson (NYSE:JNJ) announced that the Food and Drug Administration had issued a complete response letter for their anticoagulant, Xarelto...
Keep Reading →
March 6 - News
Billionaire hedge fund manager David Tepper posted outstanding 2012 performance; he brought in $2.2 billion and returned some 30% for his hedge fund Appaloosa Management.
Keep Reading →
March 6 - Hedge Funds
Since everyone loves a winner, it's reasonable to assume that everyone hates a loser -- everyone but short sellers, at least. These contrarian investors bet that hot stocks...
Keep Reading →
March 6 - News
Are we beating up too much on Eli Lilly & Co.
Keep Reading →
March 6 - News
The market has been less than thrilled about an upcoming Supreme Court decision on the legality of the best-selling analytical test of Myriad Genetics, Inc. (NASDAQ:MYGN) .
Keep Reading →
March 5 - News
Do good things come in small packages for big pharma? Most of investors' attention is given to blockbuster drugs and drugs that have the potential to be blockbusters.
Keep Reading →
March 5 - News
Hello and welcome, readers. I’d like to issue an informal apology for the delay in writing in recent weeks.
Keep Reading →
March 4 - News
Mirror, mirror, on the wall, who's the frailest big pharma of all? The patent cliff has certainly taken its toll over the past couple of years, weakening several successful pharmaceutical...
Keep Reading →
March 1 - News
The rally from November lows has pushed many stocks toward rich P/E valuations, although the current spate of selling is doing its bit to bring these down.
Keep Reading →
February 27 - News
Are Bristol Myers Squibb Co. (NYSE:BMY) and Eli Lilly & Co.
Keep Reading →
February 25 - News
The Dow Jones Industrial Average breached the 4,000-point barrier for the first time in its history on Feb. 23, 1995, closing at 4,003.33.
Keep Reading →
February 23 - News
Irritable bowel syndrome has no organic cause and treating it usually depends on reducing symptoms of chronic abdominal pain, bloating, and gastric discomfort.
Keep Reading →
February 22 - News
After coming within striking distance of its all-time high, the Dow Jones Industrial Average pulled back sharply yesterday, dropping 108 points after the Fed's committee members...
Keep Reading →
February 22 - News
Analysts wonder if other drug companies will follow in the footsteps of Abbott Laboratories (NYSE:ABT) and spinoff different parts of their business.
Keep Reading →
February 21 - News
When the word "biotechnology" gets thrown around in the pharmaceutical industry, it often implies the biomanufacturing of biologic drugs, such as therapeutic proteins.
Keep Reading →
February 20 - News
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company NewLink Genetics Corp...
Keep Reading →
February 20 - News
Make no bones about it -- Zoetis Inc (NYSE:ZTS) is one expensive stock. It even might be the most expensive health-care stock for its size.
Keep Reading →
February 19 - News
It's now more than halfway through the period that Eli Lilly & Co. (NYSE:LLY) has called its "years YZ," a term describing the years spanning from 2011 to 2014.
Keep Reading →
February 19 - News
Pfizer Inc. (NYSE:PFE) faced a rough 2012 after Lipitor's loss of exclusivity in November 2011.
Keep Reading →
February 18 - News
